GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC

RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...

RBC Capital Remains a Buy on GH Research (GHRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), BioCryst (BCRX) a...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

GH Research ( ($GHRS) ) has issued an announcement. On August 6, 2026, GH Research PLC filed a Form 6-K reporting its second quarter 2026 financial...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GHRS	$29.50	-2.54%	142.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GHRS	$29.50	-2.5%	142.35K
3
4
5
6

GHRS

GHRS

Get GH Research PLC Data in Excel

Get GH Research PLC Data in Excel